Access by Design, Benefits if Convenient: A Closer Look at the Pandemic Influenza Preparedness Framework's Standard Material Transfer Agreements
Identifieur interne : 000381 ( Main/Exploration ); précédent : 000380; suivant : 000382Access by Design, Benefits if Convenient: A Closer Look at the Pandemic Influenza Preparedness Framework's Standard Material Transfer Agreements
Auteurs : Michelle F. RourkeSource :
- The Milbank Quarterly [ 0887-378X ] ; 2019.
Descripteurs français
- KwdFr :
- MESH :
English descriptors
- KwdEn :
- MESH :
- prevention & control : Influenza, Human, Pandemics.
- standards : Specimen Handling.
- Global Health, Humans, International Cooperation, Orthomyxoviridae, Transfer Agreement, World Health Organization.
Abstract
Securing access to pathogen samples for research purposes is crucial for pandemic preparedness and responding to infectious disease outbreaks. The This analysis reveals that during an influenza pandemic, the PIP Framework will safeguard access to virus samples but may not be as effective in delivering the associated benefits, like vaccines and antivirals, to countries in need. The PIP Framework's deficiencies must be addressed before an influenza pandemic and before this ABS model is extended to other human pathogens.
The World Health Organization (WHO) adopted the
I analyzed the PIP Framework, its SMTAs, and secondary sources to determine whether the PIP Framework will effectively function as an ABS instrument during an influenza pandemic.
The SMTAs do not create any direct or binding agreements between Member States and third‐party recipients of influenza viruses. In the lead‐up to and during a pandemic, the SMTA1 secures access to influenza viruses for the WHO, and the SMTA2 secures access for commercial users of virus samples, but the SMTA2 may be ineffective in securing tangible benefits for the sovereign providers of those materials.
As the international community starts to consider how to best regulate access to nonpandemic influenza pathogen samples, it is imperative that we first address the shortcomings of the only pathogen‐specific international ABS instrument available, and we should do so before it is put to the ultimate test.
Url:
DOI: 10.1111/1468-0009.12364
PubMed: 30637812
PubMed Central: 6422609
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000761
- to stream Pmc, to step Curation: 000761
- to stream Pmc, to step Checkpoint: 000099
- to stream PubMed, to step Corpus: 000180
- to stream PubMed, to step Curation: 000180
- to stream PubMed, to step Checkpoint: 000182
- to stream Ncbi, to step Merge: 001F13
- to stream Ncbi, to step Curation: 001F13
- to stream Ncbi, to step Checkpoint: 001F13
- to stream Main, to step Merge: 000380
- to stream Main, to step Curation: 000381
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Access by Design, Benefits if Convenient: A Closer Look at the Pandemic Influenza Preparedness Framework's Standard Material Transfer Agreements</title>
<author><name sortKey="Rourke, Michelle F" sort="Rourke, Michelle F" uniqKey="Rourke M" first="Michelle F." last="Rourke">Michelle F. Rourke</name>
<affiliation><nlm:aff id="milq12364-aff-0001"></nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">30637812</idno>
<idno type="pmc">6422609</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422609</idno>
<idno type="RBID">PMC:6422609</idno>
<idno type="doi">10.1111/1468-0009.12364</idno>
<date when="2019">2019</date>
<idno type="wicri:Area/Pmc/Corpus">000761</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000761</idno>
<idno type="wicri:Area/Pmc/Curation">000761</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000761</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000099</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000099</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:30637812</idno>
<idno type="wicri:Area/PubMed/Corpus">000180</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000180</idno>
<idno type="wicri:Area/PubMed/Curation">000180</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000180</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000182</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000182</idno>
<idno type="wicri:Area/Ncbi/Merge">001F13</idno>
<idno type="wicri:Area/Ncbi/Curation">001F13</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001F13</idno>
<idno type="wicri:doubleKey">0887-378X:2019:Rourke M:access:by:design</idno>
<idno type="wicri:Area/Main/Merge">000380</idno>
<idno type="wicri:Area/Main/Curation">000381</idno>
<idno type="wicri:Area/Main/Exploration">000381</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Access by Design, Benefits if Convenient: A Closer Look at the Pandemic Influenza Preparedness Framework's Standard Material Transfer Agreements</title>
<author><name sortKey="Rourke, Michelle F" sort="Rourke, Michelle F" uniqKey="Rourke M" first="Michelle F." last="Rourke">Michelle F. Rourke</name>
<affiliation><nlm:aff id="milq12364-aff-0001"></nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">The Milbank Quarterly</title>
<idno type="ISSN">0887-378X</idno>
<idno type="eISSN">1468-0009</idno>
<imprint><date when="2019">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Global Health</term>
<term>Humans</term>
<term>Influenza, Human (prevention & control)</term>
<term>International Cooperation</term>
<term>Orthomyxoviridae</term>
<term>Pandemics (prevention & control)</term>
<term>Specimen Handling (standards)</term>
<term>Transfer Agreement</term>
<term>World Health Organization</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Accord transfert malade</term>
<term>Coopération internationale</term>
<term>Grippe humaine ()</term>
<term>Humains</term>
<term>Organisation mondiale de la santé</term>
<term>Orthomyxoviridae</term>
<term>Pandémies ()</term>
<term>Prélèvement biologique (normes)</term>
<term>Santé mondiale</term>
</keywords>
<keywords scheme="MESH" qualifier="normes" xml:lang="fr"><term>Prélèvement biologique</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
<term>Pandemics</term>
</keywords>
<keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Specimen Handling</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Global Health</term>
<term>Humans</term>
<term>International Cooperation</term>
<term>Orthomyxoviridae</term>
<term>Transfer Agreement</term>
<term>World Health Organization</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Accord transfert malade</term>
<term>Coopération internationale</term>
<term>Grippe humaine</term>
<term>Humains</term>
<term>Organisation mondiale de la santé</term>
<term>Orthomyxoviridae</term>
<term>Pandémies</term>
<term>Santé mondiale</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec id="milq12364-sec-0010"><p><boxed-text position="anchor" content-type="box" orientation="portrait"><caption><title>Policy Points</title>
</caption>
<p><list list-type="bullet" id="milq12364-list-0001"><list-item><p>Securing access to pathogen samples for research purposes is crucial for pandemic preparedness and responding to infectious disease outbreaks.</p>
</list-item>
<list-item><p>The <italic>Pandemic Influenza Preparedness Framework</italic>
(PIP Framework) is the only pathogen‐specific international access and benefit‐sharing (ABS) instrument.</p>
</list-item>
<list-item><p>This analysis reveals that during an influenza pandemic, the PIP Framework will safeguard access to virus samples but may not be as effective in delivering the associated benefits, like vaccines and antivirals, to countries in need.</p>
</list-item>
<list-item><p>The PIP Framework's deficiencies must be addressed before an influenza pandemic and before this ABS model is extended to other human pathogens.</p>
</list-item>
</list>
</p>
</boxed-text>
</p>
</sec>
<sec id="milq12364-sec-0020"><title>Context</title>
<p>The World Health Organization (WHO) adopted the <italic>Pandemic Influenza Preparedness Framework</italic>
(PIP Framework) after being forced to grapple with the demands of developing countries for the fairer distribution of vaccines and antivirals created using influenza viruses isolated from within their territories. Though adopted as a nonbinding resolution, the PIP Framework has been praised for its novel legal approach to access and benefit‐sharing (ABS), using Standard Material Transfer Agreements (SMTAs) to create binding terms and conditions on both providers and users of PIP biological materials. The PIP Framework's SMTA1 regulates the movement of influenza viruses with human pandemic potential through the WHO's Global Influenza Surveillance and Response System (GISRS) as it operates to monitor the spread of seasonal influenza and detect the emergence of pandemic strains. Member States give consent to the WHO to transfer their materials to third parties under the terms of a negotiated SMTA2. The SMTA2 details benefits such as vaccines and antivirals to be made available to the WHO for distribution in the event of an influenza pandemic.</p>
</sec>
<sec id="milq12364-sec-0030"><title>Methods</title>
<p>I analyzed the PIP Framework, its SMTAs, and secondary sources to determine whether the PIP Framework will effectively function as an ABS instrument during an influenza pandemic.</p>
</sec>
<sec id="milq12364-sec-0040"><title>Findings</title>
<p>The SMTAs do not create any direct or binding agreements between Member States and third‐party recipients of influenza viruses. In the lead‐up to and during a pandemic, the SMTA1 secures access to influenza viruses for the WHO, and the SMTA2 secures access for commercial users of virus samples, but the SMTA2 may be ineffective in securing tangible benefits for the sovereign providers of those materials.</p>
</sec>
<sec id="milq12364-sec-0050"><title>Conclusions</title>
<p>As the international community starts to consider how to best regulate access to nonpandemic influenza pathogen samples, it is imperative that we first address the shortcomings of the only pathogen‐specific international ABS instrument available, and we should do so before it is put to the ultimate test.</p>
</sec>
</div>
</front>
</TEI>
<affiliations><list></list>
<tree><noCountry><name sortKey="Rourke, Michelle F" sort="Rourke, Michelle F" uniqKey="Rourke M" first="Michelle F." last="Rourke">Michelle F. Rourke</name>
</noCountry>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000381 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000381 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= PandemieGrippaleV1 |flux= Main |étape= Exploration |type= RBID |clé= PMC:6422609 |texte= Access by Design, Benefits if Convenient: A Closer Look at the Pandemic Influenza Preparedness Framework's Standard Material Transfer Agreements }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:30637812" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a PandemieGrippaleV1
![]() | This area was generated with Dilib version V0.6.34. | ![]() |